Eli Lilly and Co (LLY) on Thursday said a panel of the U.S. Food and Drug Administration has supported approval of its investigational drug necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with advanced squamous non-small cell lung cancer ("NSCLC").
While the FDA is not bound to follow the advice of the Oncologic Drugs Advisory Committee, the agency normally does so.
Squamous NSCLC is a devastating and difficult-to-treat form of lung cancer. The five-year survival rate for patients with metastatic disease is less than five percent.
Necitumumab in combination with gemcitabine and cisplatin is the first regimen to show a significant improvement in overall survival over chemotherapy alone, specifically in the first-line setting, Eli Lilly said.
The FDA is expected to make a decision on Lilly's biologics license application for necitumumab later this year.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.